All providers
Sign in
Sign up to use California HCAI prescription drug price reports (WAC increases and new drugs)
Firecrawl Alexandria
Life sciences

California HCAI prescription drug price reports (WAC increases and new drugs)

California's prescription drug cost transparency reports (CTRx, SB 17) from the Department of Health Care Access and Information (HCAI), published on the CalHHS Open Data Portal. Manufacturers report wholesale acquisition cost (WAC, list price) increases of more than 16% over three years for drugs costing over $40 per course of therapy, with the increase, the new WAC, patent expiry, sales, their stated reasons and any acquisition, plus a five-year WAC history per report; and new drugs introduced at a WAC above the Medicare Part D specialty-drug threshold, with launch WAC, marketing and pricing plan, estimated patients and FDA breakthrough and priority review flags. The current year's monthly update and annual files back to 2019, searchable by drug, NDC, manufacturer and date, with derived increase percentages including the statute's three-year measure. CC BY; every result carries HCAI's attribution.

Try in Agent
Which drugs had WAC increases over 16% in California this year?

Try California HCAI prescription drug price reports (WAC increases and new drugs) now.

Choose an example or ask your own question.

California HCAI prescription drug price reports (WAC increases and new drugs)
TRY ASKING
1Request
string

Drug product description to match, case-insensitively anywhere in it: a brand (`skyrizi`, `Fyarro`), an ingredient as the manufacturer wrote it, a strength or a package form.

string

Brand or Generic, as the manufacturer classified the drug. Only the current year's monthly file reports it; with an annual year this is invalid_input.

string

number

Reports per page.

number

Only increases of at least this percent over the WAC just before them (`increase_percent`, derived). The statute measures against the WAC three years earlier instead (`three_year_increase_percent`).

string

Order of results: latest WAC effective date first (default), or largest `increase_percent` first.

5 credits
Codefollows the fields above
const result = await firecrawl.scrape({
  alexandria: {
    provider: "data-chhs-ca-gov",
    capability: "wac-increases/search",
    options: {
      limit: 10,
      min_increase_percent: 16,
      sort: "increase_percent_desc",
    },
  },
});
2Response example

This is a sample shape. Press Run to see live data from California HCAI prescription drug price reports (WAC increases and new drugs).

{
  "file_name": "wac-increase-data-jan-sept-2026.csv",
  "file_url": "https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/dda8a083-bc81-4f6d-b02f-935a2df70328/download/wac-increase-data-jan-sept-2026.csv",
  "history_file_url": null,
  "license": {
    "attribution": "Source: California Department of Health Care Access and Information (HCAI), Cost Transparency Report on prescription drugs (CTRx), Prescription Drug Wholesale Acquisition Cost (WAC) Increases, published on the California Open Data Portal under CC BY.",
    "name": "Creative Commons Attribution (CC BY)",
    "url": "https://data.ca.gov/dataset/prescription-drug-wholesale-acquisition-cost-wac-increases"
  },
  "next_offset": 10,
  "results": [
    {
      "acquisition": {
        "acquired_from": "Pierre Fabre Pharmaceuticals Inc.",
        "date": "2026-02-27",
        "price": 14000000,
        "price_comment": null,
        "price_nonpublic": false,
        "wac_at_acquisition": 625.38,
        "wac_at_introduction": 375,
        "wac_year_prior_to_acquisition": 625.38,
        "year_introduced": 2014
      },
      "change_improvement_description": "No change or improvement.",
      "change_improvement_nonpublic": false,
      "cost_increase_factors": null,
      "cost_increase_factors_nonpublic": true,
      "date_reported": "2026-07-30",
      "drug_category": "Brand",
      "drug_product_description": "Hemangeol (propranolol hydrochloride) Oral Solution, 4.28 mg/ mL, 120 mL bottle",
      "drug_source_type": "Single Source Drug",
      "general_comments": null,
      "gross_sales_nonpublic": true,
      "gross_sales_us_dollars": null,
      "history": null,
      "increase_percent": 699.51,
      "manufacturer": "Eton Pharmaceuticals, Inc.",
      "manufacturer_id": "Rx0000270",
      "ndc": "71863013212",
      "ndc_5_4_2": "71863-0132-12",
      "patent_expiration_date": "2028-10-16",
      "supporting_documents_url": null,
      "three_year_increase_percent": null,
      "unit_sales_volume_nonpublic": false,
      "unit_sales_volume_us": null,
      "wac_after_increase": 5000,
      "wac_before_increase": 625.38,
      "wac_effective_date": "2026-05-11",
      "wac_increase_amount": 4374.62
    },
    {
      "acquisition": null,
      "change_improvement_description": null,
      "change_improvement_nonpublic": true,
      "cost_increase_factors": "PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.",
      "cost_increase_factors_nonpublic": false,
      "date_reported": "2026-02-13",
      "drug_category": "Generic",
      "drug_product_description": "TRIHEXYPHENIDYL HYDROCHLORIDE 0.4mg/mL Oral Solution, 473mL Bottle [Qty: 1]",
      "drug_source_type": "Non-innovator Multiple Source Drug",
      "general_comments": null,
      "gross_sales_nonpublic": true,
      "gross_sales_us_dollars": null,
      "history": null,
      "increase_percent": 480,
      "manufacturer": "Pharmaceutical Associates, Inc",
      "manufacturer_id": "Rx0000135",
      "ndc": "00121065816",
      "ndc_5_4_2": "00121-0658-16",
      "patent_expiration_date": null,
      "supporting_documents_url": null,
      "three_year_increase_percent": null,
      "unit_sales_volume_nonpublic": false,
      "unit_sales_volume_us": null,
      "wac_after_increase": 247.37,
      "wac_before_increase": 42.65,
      "wac_effective_date": "2026-02-02",
      "wac_increase_amount": 204.72
    },
    {
      "acquisition": null,
      "change_improvement_description": null,
      "change_improvement_nonpublic": true,
      "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.",
      "cost_increase_factors_nonpublic": false,
      "date_reported": "2026-04-30",
      "drug_category": "Brand",
      "drug_product_description": "Hydromorphone Hydrochloride 2 mg/ml per Single-Dose vial 10",
      "drug_source_type": "Innovator Multiple Source Drug",
      "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.",
      "gross_sales_nonpublic": true,
      "gross_sales_us_dollars": null,
      "history": null,
      "increase_percent": 377.01,
      "manufacturer": "Pfizer",
      "manufacturer_id": "Rx0000006",
      "ndc": "00409336510",
      "ndc_5_4_2": "00409-3365-10",
      "patent_expiration_date": null,
      "supporting_documents_url": null,
      "three_year_increase_percent": null,
      "unit_sales_volume_nonpublic": false,
      "unit_sales_volume_us": null,
      "wac_after_increase": 202.06,
      "wac_before_increase": 42.36,
      "wac_effective_date": "2026-01-01",
      "wac_increase_amount": 159.7
    },
    {
      "acquisition": null,
      "change_improvement_description": null,
      "change_improvement_nonpublic": true,
      "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.",
      "cost_increase_factors_nonpublic": false,
      "date_reported": "2026-04-30",
      "drug_category": "Generic",
      "drug_product_description": "Butorphanol Tartrate 2 mg/mL (4 mg/2 mL) Single Dose Glass Fliptop Vial 10",
      "drug_source_type": "Non-innovator Multiple Source Drug",
      "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.",
      "gross_sales_nonpublic": true,
      "gross_sales_us_dollars": null,
      "history": null,
      "increase_percent": 377,
      "manufacturer": "Pfizer",
      "manufacturer_id": "Rx0000006",
      "ndc": "00409162602",
      "ndc_5_4_2": "00409-1626-02",
      "patent_expiration_date": null,
      "supporting_documents_url": null,
      "three_year_increase_percent": null,
      "unit_sales_volume_nonpublic": false,
      "unit_sales_volume_us": null,
      "wac_after_increase": 931.77,
      "wac_before_increase": 195.34,
      "wac_effective_date": "2026-01-01",
      "wac_increase_amount": 736.43
    },
    {
      "acquisition": null,
      "change_improvement_description": null,
      "change_improvement_nonpublic": true,
      "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.",
      "cost_increase_factors_nonpublic": false,
      "date_reported": "2026-04-30",
      "drug_category": "Brand",
      "drug_product_description": "Demerol™ 50 mg/mL (1,500 mg/30 mL) Multiple Dose Glass Fliptop Vial 1",
      "drug_source_type": "Innovator Multiple Source Drug",
      "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.",
      "gross_sales_nonpublic": true,
      "gross_sales_us_dollars": null,
      "history": null,
      "increase_percent": 377,
      "manufacturer": "Pfizer",
      "manufacturer_id": "Rx0000006",
      "ndc": "00409118130",
      "ndc_5_4_2": "00409-1181-30",
      "patent_expiration_date": null,
      "supporting_documents_url": null,
      "three_year_increase_percent": null,
      "unit_sales_volume_nonpublic": false,
      "unit_sales_volume_us": null,
      "wac_after_increase": 655.45,
      "wac_before_increase": 137.41,
      "wac_effective_date": "2026-01-01",
      "wac_increase_amount": 518.04
    },
    {
      "acquisition": null,
      "change_improvement_description": null,
      "change_improvement_nonpublic": true,
      "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.",
      "cost_increase_factors_nonpublic": false,
      "date_reported": "2026-04-30",
      "drug_category": "Generic",
      "drug_product_description": "Dextran 500 mL (10% LMD in 0.9% Sodium Chloride) Flexible Container 12",
      "drug_source_type": "Non-innovator Multiple Source Drug",
      "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.",
      "gross_sales_nonpublic": true,
      "gross_sales_us_dollars": null,
      "history": null,
      "increase_percent": 377,
      "manufacturer": "Pfizer",
      "manufacturer_id": "Rx0000006",
      "ndc": "00409741903",
      "ndc_5_4_2": "00409-7419-03",
      "patent_expiration_date": null,
      "supporting_documents_url": null,
      "three_year_increase_percent": null,
      "unit_sales_volume_nonpublic": false,
      "unit_sales_volume_us": null,
      "wac_after_increase": 3972.41,
      "wac_before_increase": 832.79,
      "wac_effective_date": "2026-01-01",
      "wac_increase_amount": 3139.62
    },
    {
      "acquisition": null,
      "change_improvement_description": null,
      "change_improvement_nonpublic": true,
      "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.",
      "cost_increase_factors_nonpublic": false,
      "date_reported": "2026-04-30",
      "drug_category": "Generic",
      "drug_product_description": "Dextran 500 mL (10% LMD in 5% Dextrose) Flexible Container 12",
      "drug_source_type": "Non-innovator Multiple Source Drug",
      "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.",
      "gross_sales_nonpublic": true,
      "gross_sales_us_dollars": null,
      "history": null,
      "increase_percent": 377,
      "manufacturer": "Pfizer",
      "manufacturer_id": "Rx0000006",
      "ndc": "00409741803",
      "ndc_5_4_2": "00409-7418-03",
      "patent_expiration_date": null,
      "supporting_documents_url": null,
      "three_year_increase_percent": null,
      "unit_sales_volume_nonpublic": false,
      "unit_sales_volume_us": null,
      "wac_after_increase": 3809.94,
      "wac_before_increase": 798.73,
      "wac_effective_date": "2026-01-01",
      "wac_increase_amount": 3011.21
    },
    {
      "acquisition": null,
      "change_improvement_description": null,
      "change_improvement_nonpublic": true,
      "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.",
      "cost_increase_factors_nonpublic": false,
      "date_reported": "2026-04-30",
      "drug_category": "Generic",
      "drug_product_description": "Hydromorphone Hydrochloride 10 mg/mL (10 mg/mL) Single Dose Glass Fliptop Vial 10",
      "drug_source_type": "Non-innovator Multiple Source Drug",
      "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.",
      "gross_sales_nonpublic": true,
      "gross_sales_us_dollars": null,
      "history": null,
      "increase_percent": 377,
      "manufacturer": "Pfizer",
      "manufacturer_id": "Rx0000006",
      "ndc": "00409263401",
      "ndc_5_4_2": "00409-2634-01",
      "patent_expiration_date": null,
      "supporting_documents_url": null,
      "three_year_increase_percent": null,
      "unit_sales_volume_nonpublic": false,
      "unit_sales_volume_us": null,
      "wac_after_increase": 780.56,
      "wac_before_increase": 163.64,
      "wac_effective_date": "2026-01-01",
      "wac_increase_amount": 616.92
    },
    {
      "acquisition": null,
      "change_improvement_description": null,
      "change_improvement_nonpublic": true,
      "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.",
      "cost_increase_factors_nonpublic": false,
      "date_reported": "2026-04-30",
      "drug_category": "Generic",
      "drug_product_description": "Verapamil Hydrochloride 2.5 mg/mL (5 mg/2 mL) Glass Ampul 5",
      "drug_source_type": "Non-innovator Multiple Source Drug",
      "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.",
      "gross_sales_nonpublic": true,
      "gross_sales_us_dollars": null,
      "history": null,
      "increase_percent": 377,
      "manufacturer": "Pfizer",
      "manufacturer_id": "Rx0000006",
      "ndc": "00409401101",
      "ndc_5_4_2": "00409-4011-01",
      "patent_expiration_date": null,
      "supporting_documents_url": null,
      "three_year_increase_percent": null,
      "unit_sales_volume_nonpublic": false,
      "unit_sales_volume_us": null,
      "wac_after_increase": 436.5,
      "wac_before_increase": 91.51,
      "wac_effective_date": "2026-01-01",
      "wac_increase_amount": 344.99
    },
    {
      "acquisition": null,
      "change_improvement_description": null,
      "change_improvement_nonpublic": true,
      "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.",
      "cost_increase_factors_nonpublic": false,
      "date_reported": "2026-04-30",
      "drug_category": "Brand",
      "drug_product_description": "Hydromorphone Hydrochloride 4 mg/mL (4 mg/1 mL) Carpuject™ Luer Lock Glass Syringe (no needle) 10",
      "drug_source_type": "Innovator Multiple Source Drug",
      "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.",
      "gross_sales_nonpublic": true,
      "gross_sales_us_dollars": null,
      "history": null,
      "increase_percent": 376.95,
      "manufacturer": "Pfizer",
      "manufacturer_id": "Rx0000006",
      "ndc": "00409130431",
      "ndc_5_4_2": "00409-1304-31",
      "patent_expiration_date": null,
      "supporting_documents_url": null,
      "three_year_increase_percent": null,
      "unit_sales_volume_nonpublic": false,
      "unit_sales_volume_us": null,
      "wac_after_increase": 150,
      "wac_before_increase": 31.45,
      "wac_effective_date": "2026-01-01",
      "wac_increase_amount": 118.55
    }
  ],
  "source_updated_at": "2026-10-05",
  "source_url": "https://data.chhs.ca.gov/dataset/prescription-drug-wholesale-acquisition-cost-wac-increases",
  "total_count": 100,
  "year": 2026
}

Source: California Department of Health Care Access and Information (HCAI), Cost Transparency Report on prescription drugs (CTRx): Prescription Drug Wholesale Acquisition Cost (WAC) Increases and Prescription Drugs Introduced to Market, published on the California Open Data Portal under Creative Commons Attribution (CC BY). (https://data.ca.gov/dataset/prescription-drug-wholesale-acquisition-cost-wac-increases)

Related providers

Browse the library
//
Get started
//
Give your agent California HCAI prescription drug price reports (WAC increases and new drugs).
One API key for the live web and every provider in Alexandria.
Use California HCAI prescription drug price reports (WAC increases and new drugs)Explore Alexandria
Are you an AI agent? See setup options